Order results by:
Issue | Title | |
Vol 14, No 4 (2021) | Hepatoprotective effects of chondroitin sulfate and glucosamine sulfate | Abstract similar documents |
I. Yu. Torshin, A. M. Lila, O. A. Gromova | ||
"... Background. Long-term use of chondroprotective agents – chondroitin sulfate (CS) and glucosamine ..." | ||
Vol 16, No 4 (2023) | Oncoprotective effects of chondroprotectors: glucosamine, chondroitin sulfate and undenatured type II collagen | Abstract similar documents |
I. Yu. Torshin, A. G. Chuchalin, O. A. Gromova | ||
"... effects of chondroprotectors: chondroitin sulfate (CS), glucosamine (including glucosamine sulfate, GS ..." | ||
Vol 15, No 1 (2022) | Perioperative pharmacotherapy for endoprosthetics: potential of chondroitin sulfate and glucosamine sulfate | Abstract similar documents |
I. Yu. Torshin, T. B. Minasov, N. V. Zagorodniy, A. M. Lila, O. A. Gromova | ||
"... . The unique spectrum of anti-inflammatory effect of chondroprotectors based on chondroitin sulfate ..." | ||
Vol 14, No 4 (2021) | Prospects of using chondroprotectors for the treatment of pulmonary pathology | Abstract similar documents |
I. Yu. Torshin, O. A. Gromova, A. G. Chuchalin | ||
"... Background. The complex mechanisms of action of chondroitin sulfate (CS) and glucosamine sulfate ..." | ||
Vol 15, No 3 (2022) | Prospects for the use of chondroitin sulfate and glucosamine sulfate in the treatment of patients with obesity-associated osteoarthritis (metabolic syndrome) | Abstract similar documents |
I. Yu. Torshin, О. A. Gromova, A. M. Lila | ||
"... chondroitin sulfates (CS) lead to chronic inflammation and the development of a complex of comorbid ..." | ||
Vol 13, No 2 (2020) | Is it worthwhile rethinking the positive experience of the last 50 years of using chondroitin sulfates against atherosclerosis? | Abstract similar documents |
A. M. Lila, I. Yu. Torshin, O. A. Gromova | ||
"... Chondroitin sulfate (CS) and glucosamine sulfate (GS) are used in the treatment of osteoarthritis ..." | ||
Online First | Osteoarthritis therapy misconcepts | Abstract similar documents |
O. A. Shavlovskaya, О. А. Gromova, I. Yu. Torshin, I. D. Romanov | ||
"... are prescribed (according to the opinion of European experts (2019)) that are as follows: chondroitin sulfate (CS ..." | ||
Vol 13, No 4 (2020) | Acute issues in the pharmacotherapy of hand osteoarthritis | Abstract similar documents |
O. A. Gromova, I. Yu. Torshin, A. V. Naumov, L. V. Vasilyeva, Ye. F. Yevstratova, А. N. Gromov | ||
"... therapy include steroid drugs, chondroitin sulfate (CS), glucosamine sulfate (GS), and vitamin D ..." | ||
Vol 16, No 2 (2023) | From misconceptions to reasonable osteoarthritis patients therapy | Abstract similar documents |
O. A. Shavlovskaya, О. А. Gromova, I. Yu. Torshin, I. D. Romanov | ||
"... of European experts (2019): chondroitin sulfate (CS), glucosamine sulfate (GS), diacerein, avocado soybean ..." | ||
Vol 16, No 3 (2023) | Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy | Abstract similar documents |
O. A. Shavlovskaya, О. А. Gromova, A. Yu. Kochish, Yu. D. Yukhnovskaya, I. D. Romanov, I. A. Bokova | ||
"... sulfate, glucosamine sulfate, undenatured type II collagen, vitamin D. Each of them has symptom-modifying ..." | ||
Vol 16, No 4 (2023) | DMOADs and DMARDs in the treatment of patients with joint and spine diseases | Abstract PDF (Eng) similar documents |
O. A. Shavlovskaya | ||
Vol 13, No 3 (2020) | Chemomicrobiomic analysis of glucosamine sulfate, prebiotics and non-steroidal anti-inflammatory drugs | Abstract similar documents |
O. A. Gromova, I. Yu. Torshin, A. V. Naumov, V. A. Maksimov | ||
"... of glucosamine sulfate (GS), diclofenac, acetylsalicylic acid (ASA), and three prebiotics (lactose, lactulose ..." | ||
Vol 14, No 1 (2021) | Differences in the standardization of medicinal products based on extracts of chondroitin sulfate | Abstract similar documents |
O. A. Gromova, I. Yu. Torshin, B. Ts. Zaychik, E. V. Shikh, A. O. Ruzhitskiy, A. N. Galustyan, I. S. Sardaryan, I. V. Sarvilina | ||
"... chondroitin sulfate (CS) based on natural extracts. Material and methods. Five samples were studied for each ..." | ||
Vol 12, No 4 (2019) | Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis | Abstract similar documents |
I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva | ||
"... containing chondroitin sulfate or modifying its biosynthesis in patients with stage II knee osteoarthritis ..." | ||
Vol 13, No 4 (2020) | Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard | Abstract similar documents |
I. Yu. Torshin, A. M. Lila, A. V. Naumov, A. Yu. Kochish, L. I. Alekseeva, E. A. Taskina, I. V. Sarvilina, A. N. Galustyan, A. N. Gromov, A. K. Khadzhidis, L. V. Vasilieva, E. F. Yevstratova, M. I. Udovika, O. A. Gromova | ||
Vol 14, No 3 (2021) | The concept of syndromic diagnoses of osteoarthritis and back pain as a cause of therapy failure | Abstract similar documents |
M. V. Putilina, N. V. Teplova, O. S. Gerasimova | ||
"... -acting drugs containing chondroitin sulfate (Chondroguard®), which will accelerate the onset ..." | ||
Vol 14, No 2 (2021) | Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy | Abstract similar documents |
I. Yu. Torshin, O. A. Gromova, A. G. Chuchalin, Yu. I. Zhuravlev | ||
"... stress. Glucosamine sulfate was found to have the best safety profile and minimum effects on the healthy ..." | ||
Vol 16, No 1 (2023) | Development of a verified osteoarthritis risk scale based on a cross-sectional study of clinical and anamnestic parameters and pharmacological anamnesis of patients | Abstract similar documents |
I. Yu. Torshin, А. М. Lila, N. V. Zagorodniy, А. G. Nazarenko, О. N. Tkacheva, Е. N. Dudinskaya, L. I. Alekseeva, Е. А. Taskina, I. V. Sarvilina, О. А. Shavlovskaya, A. B. Danilov, Т. B. Minasov, А. N. Galustyan, S. I. Malyavskaya, А. N. Gromov, Е. Yu. Egorova, L. V. Vasilyeva, E. F. Evstratova, I. V. Gogoleva, L. E. Fedotova, М. I. Udovika, V. A. Maximov, А. S. Povzun, О. А. Gromova | ||
"... of chondroitin sulfate (CS) and glucosamine sulfate (GS) is promising. The evidence for CS/GS is extensive ..." | ||
Vol 15, No 1 (2022) | Application of chondroprotective agents to inhibit osteodestructive processes in the subchondral bone in patients with osteoarthritis | Abstract PDF (Eng) similar documents |
О. А. Gromova, А. М. Lila, I. Yu. Torshin, I. А. Reier | ||
"... agents (chondroitin sulfate (CS), glucosamine sulfate (GS), and undenaturated collagen) block ..." | ||
Vol 14, No 1 (2021) | Perspectives of osteoarthritis prevention and therapy personification based on the analysis of comorbid background, genetic polymorphisms and microelement status | Abstract similar documents |
I. Yu. Torshin, A. M. Lila, A. V. Naumov, I. S. Sardaryan, T. E. Bogacheva, T. R. Grishina, I. V. Gogoleva, O. A. Limanova, O. A. Gromova | ||
"... on the obtained results the prospects for the use of chondroitin sulfate and glucosamine sulfate in patients ..." | ||
Vol 14, No 3 (2021) | Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer | Abstract similar documents |
O. P. Bobrova, S. K. Zyryanov, N. A. Shnayder, M. M. Petrova | ||
"... tree in patients receiving morphine sulfate (n=45) and fentanyl TTS (n=45) for pain relief ..." | ||
Vol 10, No 2 (2017) | PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY | Abstract similar documents |
A. V. Rudakova, S. A. Protsenko, I. A. Koroleva | ||
"... Treatment of patients with non-small-cell lung cancer (NSCLC) is one of important problems ..." | ||
Vol 17, No 2 (2024) | Study of lithium carbonate and ascorbate proliferative properties on transplantable Lewis lung carcinoma metastasis model | Abstract similar documents |
D. E. Frolova, I. Yu. Torshin, V. V. Rastashansky, M. V. Filimonova, O. A. Gromova | ||
"... lung carcinoma (LLC) growth and metastasis in F1 mice (CBA × C57Bl/6j). In the first series ..." | ||
Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract similar documents |
A. U. Kulikov | ||
"... Abstract: lung cancer takes the second place in the general structure of incidence of malignant ..." | ||
Vol 14, No 2 (2021) | Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price | Abstract similar documents |
D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov | ||
"... for stage IV non-small-cell lung cancer with oral vinorelbine and pemetrexed as well as first-line ..." | ||
Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
"... with lorlatinib in adult patients with advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung ..." | ||
Online First | Antitumor effects of vitamin B12 in vitro, in vivo, in silico | Abstract similar documents |
O. A. Gromova, D. E. Frolova, I. Yu. Torshin, M. V. Filimonova, M. A. Sorokina, I. A. Reyer, O. A. Limanova, L. E. Fedotova, L. A. Maiorova | ||
"... . Cell lines BT-474 (breast ductal carcinoma) and A549 (lung carcinoma) were used as an in vitro cell ..." | ||
Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
"... with advanced small cell lung cancer (SCLC), but with the advent of new immunological drugs, immune checkpoint ..." | ||
Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
S. К. Zyryanov, I. N. Dyakov | ||
"... patients with non-small cell lung cancer (NSCLC) in the first line of therapy. Material and methods ..." | ||
Vol 16, No 3 (2023) | Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract similar documents |
S. K. Zyryanov, I. N. Dyakov | ||
"... death protein 1 (PD-1)) in patients with advanced non-small cell lung cancer (NSCLC) after previous ..." | ||
Vol 15, No 2 (2022) | Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation | Abstract similar documents |
S. К. Zyryanov, I. N. Dyakov | ||
"... Obstructive Lung Disease (GOLD), also according to the therapy used and the frequency of exacerbations ..." | ||
Vol 16, No 1 (2023) | Non-invasive respiratory support in patients with severe community-acquired pneumonia | Abstract similar documents |
S. V. Korotchenko, D. I. Korabelnikov | ||
"... early use of intubation and artificial lung ventilation (ALV) in patients with severe pneumonia ..." | ||
Vol 13, No 4 (2020) | Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders | Abstract similar documents |
O. A. Gromova, I. Yu. Torshin, V. A. Maksimov, A. G. Chuchalin, V. G. Zgoda, А. N. Gromov, O. V. Tikhonova | ||
"... Introduction. Hemosiderosis is a pathologic condition that accompanies liver, lung, and other ..." | ||
Vol 11, No 4 (2018) | Costs of pharmacotherapy in pediatric patients with community-acquired pneumonia: mathematical and statistical analysis | Abstract similar documents |
I. A. Narkevich, O. D. Nemyatyh, D. D. Siukaeva, I. V. Pavlushkov, D. O. Ivanov, Ya. V. Panyutina | ||
"... , duration of hospital stay, cost of therapy, number of prescribed drugs, number of affected lung segments ..." | ||
Vol 17, No 1 (2024) | Chemoreactome screening of aquacobalamin and heptamethyl ester of cyanoaquacobyrinic acid cytotoxic effects on tumor cells with experimental confirmation on BT-474 and A549 cell | Abstract similar documents |
I. Yu. Torshin, M. V. Filimonova, O. A. Gromova, L. A. Maiorova, M. A. Sorokina, D. E. Frolova, A. N. Gromov, I. A. Reyer | ||
"... duct carcinoma), and A549 (lung carcinoma) cell lines. Dicyanocobyric acid heptamethyl ester ((CN)2Cby ..." | ||
Vol 17, No 4 (2024) | Study of the effect of human placenta hydrolysate in a new model of metabolic-associated fatty liver disease with iron overload | Abstract similar documents |
T. E. Bogacheva, O. A. Gromova, I. Yu. Torshin, V. I. Demidov, A. G. Kalacheva, A. A. Garanin, I. V. Gogoleva, L. E. Fedotova, O. A. Limanova, А. N. Mnatsakanyan, N. Yu. Zhidomorov, T. R. Grishina | ||
"... , a model of liver iron overload was reproduced by intraperitoneal administration of iron sulfate for 12 ..." | ||
Vol 12, No 4 (2019) | Crucial areas of the economic analysis of public cancer care | Abstract similar documents |
D. A. Andreev, K. I. Polyakova, A. A. Zavyalov, T. N. Ermolaeva, A. G. Fisun, A. D. Ermolaeva, V. A. Dubovtseva, T. E. Maksimova | ||
"... (breast, colon, prostate, lung etc.) were selected. In addition, we focused on significant studies ..." | ||
Vol 15, No 4 (2022) | Possibilities of physical therapy and electrophysical modalities in the complex therapy of pneumonia | Abstract similar documents |
D. I. Korabelnikov, V. V. Grigoryev, О. V. Efimova | ||
"... , improve blood supply to the lungs. PT contributes to the normalization of pulmonary ventilation, has ..." | ||
Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
"... / umeclidinum bromide resulted in improved lung function (an increase in FEV1 by 120% on the 169th day, 0.205 vs ..." | ||
Vol 13, No 3 (2020) | Economic burden of systemic sclerosis: systematic review | Abstract similar documents |
D. L. Klabukova, V. S. Krysanova, T. N. Ermolaeva, M. V. Davydovskaya, K. A. Kokushkin | ||
"... the clinical manifestations of the disease, lung lesions and gastrointestinal problems made the largest ..." | ||
1 - 42 of 42 Items |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)